Dataset Information

Different Gene Expression Profile in Spontaneously Hypertensive Rats Treated with Songling Xuemaikang Capsule

ABSTRACT: To study in vivo action of Songling Xuemaikang Capsule (SXC), SHRs were orally administration with high- or low-dose of SXC for 28 days.Valsartan, an angiotensin receptor antagonist, is used as a positive control drug in this study and orally administrated for 28 days. The levels of AngII, Aldosterone in serum of SHRs from different groups were analyzed, and gene expression profiling were performed in the thoracic aortakidney of SHRs, using the Whole Rat Genome Oligonucleotide Microarray. The integrated causal network analysis is performed to understand the mechanism of antihypertensive effect of SXC. The results showed that expression of 706 unique genes (p<0.05) were changed (fold change >2.0) in SHRs at a dose of 472.5 mg/kg day SXC when compared with control rats, whereas the expression of 920 unique genes were changed (fold change>2.0) at a dose of 1417.5 mg/kg/day. Those genes are involved in lipid metabolism, complement system induced immune response, inflammation and vascular and endothelial dysfunction.

ORGANISM(S): Rattus norvegicus

PROVIDER: GSE128167 | GEO | 2020/03/01

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:Abstract Background: Long-term hypertension can lead to hypertensive heart disease, which ultimately progresses to heart failure. As an angiotensin receptor blocker (ARB) antihypertensive drug, allisartan can control blood pressure and improve cardiac remodeling and cardiac dysfunction caused by hypertension. The objective of this study is to investigate the protective effects of Allisartan on the heart of spontaneously hypertensive rats (SHRs) and the underlying mechanisms. Methods: We used spontaneously hypertensive rats (SHRs) as an animal model of hypertensive heart disease and treated them with allisartan orally at a dose of 25 mg/(Kg·day). We continuously monitored the rats' blood pressure levels, measured their body and heart weights, and evaluated their cardiac structure and function using echocardiography. WGA staining and Masson trichrome staining were employed to assess the morphology of the myocardial tissue. We performed transcriptome and proteome analysis using the Solexa/Illumina sequencing platform and tandem mass tag (TMT) technology, respectively. We used immunofluorescence co-localization to analyze Nrf2 nuclear translocation, and TUNEL to detect the level of cell apoptosis. The protein and mRNA levels were determined by Western blotting and qRT-PCR, respectively. Results: Allisartan lowered blood pressure, attenuated cardiac remodeling, and improved cardiac function. Allisartan alleviated cardiomyocyte hypertrophy and cardiac fibrosis. Allisartan significantly affected the pentose phosphate pathway, fatty acid elongation, valine, leucine and isoleucine degradation, glutathione metabolism, and amino sugar and nucleotide sugar metabolism pathways in the hearts of SHRs, and upregulated the expression level of GSTM2. Allisartan activated the PI3K-AKT-Nrf2 signaling pathway and inhibited cardiomyocyte apoptosis. Conclusions: Our study determined that allisartan effectively controls blood pressure in SHRs and improves cardiac remodeling and cardiac dysfunction. Allisartan upregulates the expression level of GSTM2 in the hearts of SHRs and significantly affects glutathione metabolism shown by transcriptomics and proteomics analysis. The cardioprotective effect of allisartan may be mediated through activation of the PI3K-AKT-Nrf2 signaling pathway, upregulation of GSTM2 expression, and reduction of SHRs cardiomyocyte apoptosis.

Dataset Information

Different Gene Expression Profile in Spontaneously Hypertensive Rats Treated with Songling Xuemaikang Capsule

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets